Match tier
Likely match
Presence
Current · Arkansas
Last published
2021
Sources
OpenAlex · ORCID
Refreshed
2026-10-07
L
Landry K. Kamdem
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: St. Jude Children's Research Hospital (2008); Johannes Gutenberg University Mainz (2006); Indiana University Indianapolis (2010–2011); Indiana University School of Medicine (2010); University of Göttingen (2004–2006)
14 h-index
20 pubs
1,183 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Landry K. Kamdem's research focuses on factors influencing endocrine therapy adherence in breast cancer patients. His work has investigated the relative contributions of drug-related and patient-related elements to treatment adherence. Kamdem has published 26 scholarly works, which have garnered over 1,184 citations, and maintains an h-index of 14. He has collaborated with Sophia Tilley, Mariam F Haji-Hersi, and Caleb A Shelton, all from Harding University Main Campus, on shared publications.
Metrics
- h-index: 14
- Publications: 20
- Citations: 1,183
Selected Publications
-
Drug- and patient-related factors are the strongest predictors of endocrine therapy adherence in breast cancer patients (2021)
-
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)PMC OpenAlex
-
Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women (2019)
-
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019)
-
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium (2018)
-
Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers (2017)
-
COX2 induction: a mechanism of endocrine breast cancer resistance? (2017)
-
Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers (2015)
-
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia (2015)
Collaboration Network
Top Collaborators
Michael A. Murphy
Harding University Main Campus (US)
4 shared publications
- Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers
- Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers
- COX2 induction: a mechanism of endocrine breast cancer resistance?
- Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women
Daniel H. Atchley
University of Pikeville (US)
3 shared publications
- Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers
- Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers
- Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women
Brandi L. Clark
Harding University Main Campus (US)
3 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- COX2 induction: a mechanism of endocrine breast cancer resistance?
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Bill J. Gurley
University of Arkansas for Medical Sciences
2 shared publications
In database
- Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers
- Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women
Jingyue Xi
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Bryana J. Gregory
Harding University Main Campus
2 shared publications
In database
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Kelley M. Kidwell
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Vered Stearns
Sidney Kimmel Comprehensive Cancer Center (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Daniel F. Hayes
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Christina L. Gersch
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
James M. Rae
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
N. Lynn Henry
Huntsman Cancer Institute (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Daniel L. Hertz
University of Michigan (US)
2 shared publications
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
Laura B. Ramsey
St. Jude Children's Research Hospital (US)
1 shared publication
- Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
Laura J. Janke
St. Jude Children's Research Hospital (US)
1 shared publication
- Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
Similar Researchers
Based on overlapping research topics
John P. Lee
University of Arkansas for Medical Sciences
Health Sciences Research and Education
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies
R. P. Wheeler
University of Arkansas for Medical Sciences
Health Sciences Research and Education
Health and Medical Research Impacts
Medical Research
Martha H. Carle
University of Arkansas for Medical Sciences
Health Sciences Research and Education
Retrospective Studies
Health and Medical Research Impacts
Melaina E Taylor
University of Arkansas at Fayetteville
Health Sciences Research and Education
Cancer Treatment and Pharmacology
Health and Medical Research Impacts
Ralph Broadwater
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies
Retrospective Studies
Justin McLawhorn
University of Arkansas for Medical Sciences
Health Sciences Research and Education
Cancer Treatment and Pharmacology
Retrospective Studies